Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.71 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.62 |
| ▸ | BRAF | P15056 | 5/20 | 0.59 |
| ▸ | KDR | P35968 | 4/20 | 0.59 |
| ▸ | RET | P07949 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | FLT1 | P17948 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603544 | 0.92 | GSK3B (0.64) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL16990631 | 0.92 | RAF1 (0.68) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL171198 | 0.91 | GSK3B (0.69) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL17000012 | 0.91 | DDR2 (0.62) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL171314 | 0.91 | GSK3B (0.68) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL170909 | 0.91 | GSK3B (0.68) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL15574177 | 0.91 | DDR2 (0.65) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL171337 | 0.90 | RAF1 (0.61) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL170956 | 0.90 | RAF1 (0.65) | RAF1GSK3BDDR2BRAFKDR | |
| SCHEMBL15574765 | 0.90 | GSK3B (0.69) | RAF1GSK3BDDR2BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | claimed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | RAF1 2/4885GSK3B 1104/4885DDR2 4558/4885 |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | RAF1 3072/4885GSK3B 494/4885DDR2 1/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | RAF1 2/4885GSK3B 1104/4885DDR2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.